SMILES,Name,Conditions,NCT_Number,Phases,Unapproval Probability,Approval Probability
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O,_BIVALIRUDIN,ST ELEVATION MYOCARDIAL INFARCTION,NCT03822975,Not Applicable,0.008857169795997278,0.9911428302040028
CC(=O)[O-],_ACETATE,DEPRESSION,NCT02837432,Early Phase 1,0.12567002171977235,0.8743299782802275
CC(=O)[O-],_ACETATE,BURN,NCT01413620,Phase 1,0.07853541183564486,0.9214645881643552
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,_EXEMESTANE,OVARIAN CANCER,NCT04460807,Phase 3,0.08030893168240047,0.9196910683175996
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,_LETROZOLE,OVARIAN CANCER,NCT03378297,Early Phase 1,0.13787021662774768,0.8621297833722522
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.03928522234089375,0.9607147776591064
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.04930554779560515,0.9506944522043952
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISONE,VASCULITIS,NCT03692416,Phase 3,0.04496145289085834,0.9550385471091418
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,PROSTATE CANCER,NCT04194554,Phase 1|Phase 2,0.27600245120543204,0.7239975487945678
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,_NIRAPARIB,BREAST CANCER,NCT02826512,Phase 2,0.2031862493065748,0.7968137506934252
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,OVARIAN CANCER,NCT03464201,Phase 2,0.4214284939681546,0.5785715060318453
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,_ENZALUTAMIDE,BREAST CANCER,NCT02955394,Phase 2,0.3779085013904206,0.6220914986095795
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.19115156060282046,0.8088484393971794
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,NEOPLASMS,NCT03967223,Phase 2,0.16843572020643985,0.8315642797935598
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.03711254140077378,0.9628874585992264
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,PROSTATE CANCER,NCT03089203,Phase 1,0.19966292179271025,0.8003370782072898
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,HEPATOCELLULAR CARCINOMA,NCT04011033,Phase 2|Phase 3,0.03369401205678379,0.9663059879432164
O=P1(N(CCCl)CCCl)NCCCO1,_CYCLOPHOSPHAMIDE,RETINOBLASTOMA,NCT02870907,Phase 2,0.05814495828676289,0.9418550417132372
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,VASCULITIS,NCT03692416,Phase 3,0.05647787034063611,0.943522129659364
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,_METHOTREXATE,BREAST CANCER,NCT02897700,Phase 1,0.05666085431574348,0.9433391456842566
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,_TACROLIMUS,LYMPHEDEMA,NCT04390685,Phase 1|Phase 2,0.04730591874925647,0.9526940812507436
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,OVARIAN CANCER,NCT03814447,Early Phase 1,0.3524468074039189,0.6475531925960807
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,NEOPLASMS,NCT03967223,Phase 2,0.3702842644398144,0.6297157355601856
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,_FLUDARABINE,HEPATOCELLULAR CARCINOMA,NCT02905188,Phase 1,0.5264908581659684,0.4735091418340317
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,OVARIAN CANCER,NCT03936270,Phase 2,0.4876369105055313,0.5123630894944687
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,_PALBOCICLIB,PROSTATE CANCER,NCT02905318,Phase 2,0.4950962283307823,0.5049037716692177
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,_ANASTROZOLE,PULMONARY ARTERIAL HYPERTENSION,NCT03229499,Phase 2,0.3814060759644216,0.6185939240355781
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,_GEMCITABINE,MULTIPLE MYELOMA,NCT03442673,Phase 2,0.3832639202798329,0.6167360797201666
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,NEOPLASMS,NCT03693612,Phase 2,0.09626512387919953,0.9037348761208004
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,PERIPHERAL ARTERY DISEASE,NCT04393389,,0.132524065030869,0.8674759349691311
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,_PACLITAXEL,HEMODIALYSIS ACCESS FAILURE,NCT04285073,Not Applicable,0.059254893668841124,0.9407451063311586
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,OVARIAN CANCER,NCT03378297,Early Phase 1,0.3698558719535375,0.6301441280464624
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PROSTATE CANCER,NCT03810105,Phase 2,0.6852549889486312,0.3147450110513693
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,_OLAPARIB,PULMONARY ARTERIAL HYPERTENSION,NCT03782818,Phase 1|Phase 2,0.6166322831653634,0.38336771683463694
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_DESMOPRESSIN,"STROKE, ACUTE",NCT03696121,Phase 2,0.057293966910610325,0.9427060330893896
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_VASOPRESSIN,HEART ARREST,NCT03640949,Phase 2|Phase 3,0.04774018708660337,0.9522598129133968
NC(=O)CCC1NC(=O)C(Cc2ccccc2)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(N)CSSCC(C(=O)N2CCCC2C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC1=O.NCCCCC(NC(=O)C1CCCN1C(=O)C1CSSCC(N)C(=O)NC(Cc2ccc(O)cc2)C(=O)NC(Cc2ccccc2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,_VASOPRESSIN,HYPERTENSION,NCT04170751,Not Applicable,0.04337970877277614,0.956620291227224
N=C(N)NCCC[C@H](N)C(=O)O,_ARGININE,HEART ARREST,NCT03640949,Phase 2|Phase 3,0.05999503242357005,0.9400049675764298
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.03751958413327379,0.9624804158667262
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,HEART ARREST,NCT03640949,Phase 2|Phase 3,0.03751958413327379,0.9624804158667262
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,PNEUMONIA,NCT03852537,Phase 2,0.043076819554440086,0.95692318044556
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,_METHYLPREDNISOLONE,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.2343442554535888,0.7656557445464109
NC[C@H](O)c1ccc(O)c(O)c1,_NOREPINEPHRINE,HYPERTENSION,NCT04170751,Not Applicable,0.00907707343283272,0.9909229265671674
NC[C@H](O)c1ccc(O)c(O)c1,_NOREPINEPHRINE,HYPOTENSION DRUG-INDUCED,NCT03626454,Not Applicable,0.003401980114708321,0.9965980198852916
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,HEMORRHOID,NCT03797703,Phase 1,0.003434678153285618,0.9965653218467144
CCN(CC)CC(=O)Nc1c(C)cccc1C,_LIDOCAINE,CONTRACEPTION,NCT02799641,Not Applicable,0.003434678153285618,0.9965653218467144
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,_AMIKACIN,"SHOCK, SEPTIC",NCT04178148,Not Applicable,0.1243601123160246,0.8756398876839755
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,_MYCOPHENOLATE_MOFETIL,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03492255,Not Applicable,0.0230811035731102,0.9769188964268898
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,BREAST CANCER,NCT01646034,Phase 3,0.06464342228357879,0.9353565777164212
S=P(N1CC1)(N1CC1)N1CC1,_THIOTEPA,RETINOBLASTOMA,NCT02870907,Phase 2,0.1316769362926568,0.8683230637073431
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,ISCHEMIC HEART DISEASE,NCT03600961,,0.11545995901557768,0.8845400409844224
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,_SIROLIMUS,ANGINA PECTORIS,NCT02901353,,0.11545995901557768,0.8845400409844224
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,_MELPHALAN,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.09092014284150043,0.9090798571584996
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,_VERAPAMIL,ISCHEMIC STROKE,NCT03347786,Phase 1,0.14520395027089095,0.8547960497291089
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,DEPRESSION,NCT02837432,Early Phase 1,0.13570172797423155,0.8642982720257684
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,PROSTATE CANCER,NCT00859781,Phase 2,0.19622626906989984,0.8037737309301002
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,SEPSIS,NCT04160676,Not Applicable,0.13620810644892475,0.8637918935510751
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,"SHOCK, SEPTIC",NCT03592693,Phase 2,0.13620810644892475,0.8637918935510751
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_HYDROCORTISONE,CARDIOGENIC SHOCK,NCT03773822,Phase 3,0.13620810644892475,0.8637918935510751
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,_PREDNISOLONE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.0403236818818937,0.9596763181181064
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,PROSTATE CANCER,NCT03513211,Phase 1|Phase 2,0.08994688429839139,0.9100531157016089
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,MULTIPLE MYELOMA,NCT04163107,Phase 1,0.1174225878107518,0.8825774121892482
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,_HYDROXYCHLOROQUINE,TYPE 1 DIABETES,NCT03428945,Phase 2,0.08417800057033997,0.9158219994296598
CC(=O)Nc1ccc(O)cc1,_ACETAMINOPHEN,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.009867682527760905,0.990132317472239
CN(C)CCOC(c1ccccc1)c1ccccc1,_DIPHENHYDRAMINE,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.028126557189728597,0.9718734428102712
O=C(O)[C@H](O)[C@@H](O)C(=O)O,_TARTRATE,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT03450629,Phase 3,0.17246913020392093,0.8275308697960788
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,WALDENSTRÃ–M MACROGLOBULINEMIA,NCT04463953,Phase 2,0.027288968348549457,0.9727110316514505
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,_DEXAMETHASONE,PERIPHERAL ARTERIAL DISEASE,NCT03942601,Phase 2,0.06225274103646172,0.9377472589635384
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,_DEXTROSE,OSTEO ARTHRITIS OF THE KNEES,NCT03400631,Not Applicable,0.049987773780087764,0.9500122262199124
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,_SOMATOSTATIN,HEPATOCELLULAR CARCINOMA,NCT02799212,Phase 3,0.03944245596819985,0.9605575440318002
CC(C)NCC(O)COc1cccc2ccccc12,_PROPRANOLOL,OBSTRUCTIVE SLEEP APNEA,NCT03049306,Phase 2,0.13470016145086353,0.8652998385491365
CC(=O)Nc1nnc(S(N)(=O)=O)s1,_ACETAZOLAMIDE,"HYPERTENSION, PULMONARY",NCT02755298,Phase 2|Phase 3,0.04301280085153758,0.9569871991484622
CC12CC3CC(C)(C1)CC(N)(C3)C2,_MEMANTINE,COGNITION DISORDERS,NCT03342443,Phase 2|Phase 3,0.06754453552990232,0.9324554644700978
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,POSTOPERATIVE DELIRIUM,NCT04483596,,0.2169288766708417,0.7830711233291581
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,OBSTRUCTIVE SLEEP APNEA,NCT02484300,Not Applicable,0.13736879178040862,0.8626312082195912
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,IRRITABLE BOWEL SYNDROME,NCT04193501,Phase 3,0.010586090189096484,0.9894139098109036
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,HEART FAILURE WITH REDUCED EJECTION FRACTION,NCT03894683,Phase 2,0.010586090189096484,0.9894139098109036
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,_MELATONIN,MIGRAINE DISORDERS,NCT03597529,Phase 2,0.029864665412776575,0.9701353345872232
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,DELIRIUM,NCT04456985,Not Applicable,0.05586252542885358,0.9441374745711464
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,_FOLIC_ACID,ANEMIA,NCT04404751,Not Applicable,0.04765893088926375,0.9523410691107363
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,_BIOTIN,ANEMIA,NCT02757898,Phase 1,0.5225130113798185,0.4774869886201814
NC(=O)CC[C@H](N)C(=O)O,_GLUTAMINE,BURN,NCT00985205,Phase 3,0.6141019078591289,0.3858980921408712
NC(=O)CC[C@H](N)C(=O)O,_L-GLUTAMINE,BURN,NCT00985205,Phase 3,0.6141019078591289,0.3858980921408712
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,_AMLODIPINE,HYPERTENSION|DYSLIPIDEMIAS,NCT04074551,Phase 3,0.00568984731552245,0.9943101526844776
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,_AMLODIPINE,CEREBRAL SMALL VESSEL DISEASE,NCT03082014,Phase 3,0.012264537585953037,0.9877354624140467
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,_PERINDOPRIL,ALZHEIMER DISEASE,NCT02085265,Phase 2,0.0042479595802565094,0.9957520404197434
[F-].[Na+],_SODIUM_FLUORIDE,CAROTID ARTERY STENOSIS,NCT03353103,Phase 2,0.3135519406575595,0.6864480593424402
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,_ASCORBIC_ACID,SEPSIS,NCT04160676,Not Applicable,0.09323834329010378,0.9067616567098962
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,SEPSIS,NCT04160676,Not Applicable,0.04755077677834565,0.9524492232216544
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,DELIRIUM,NCT04214106,,0.2304963420015357,0.7695036579984642
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,_THIAMINE,CARDIAC ARREST,NCT03509662,Phase 2,0.04755077677834565,0.9524492232216544
Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,_POMALIDOMIDE,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,NCT04191616,Phase 2,0.8160257158084875,0.1839742841915125
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,_SUNITINIB,BREAST CANCER,NCT02790580,Phase 2,0.1373205392425114,0.8626794607574887
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,_RUXOLITINIB,MULTIPLE MYELOMA,NCT03110822,Phase 1,0.2831953519298821,0.7168046480701176
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,_DOXORUBICIN,RETINOBLASTOMA,NCT01783535,Phase 2,0.20029397873647184,0.799706021263528
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,_DOXORUBICIN_HYDROCHLORIDE,OVARIAN CANCER,NCT04337632,Phase 3,0.09159161747872677,0.9084083825212734
COC(=O)C(c1ccccc1)C1CCCCN1,_METHYLPHENIDATE,ANXIETY,NCT02153944,Not Applicable,0.12734616873263913,0.8726538312673608
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03953261,Phase 2,0.04798658865326383,0.9520134113467362
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,PROSTATE CANCER,NCT03769766,Phase 3,0.05675312268213292,0.9432468773178672
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,BREAST CANCER,NCT03980509,Phase 1,0.3413923910507864,0.6586076089492134
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,_CURCUMIN,"HEMATOMA, SUBDURAL, CHRONIC",NCT03845322,Early Phase 1,0.04798658865326383,0.9520134113467362
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,_VITAMIN_E,BREAST CANCER,NCT04463459,Not Applicable,0.08859469660295204,0.911405303397048
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,_CHOLECALCIFEROL,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT04011930,Phase 2,0.024372949672676985,0.9756270503273229
CN(C)C(=N)NC(=N)N,_METFORMIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.04698560347098616,0.9530143965290141
CN(C)C(=N)NC(=N)N,_METFORMIN,BREAST CANCER,NCT04559308,Phase 2,0.0025889774020024267,0.9974110225979976
CN(C)C(=N)NC(=N)N,_METFORMIN,HEART FAILURE,NCT03331861,Phase 2,0.005326953353906235,0.9946730466460936
CN(C)C(=N)NC(=N)N,_METFORMIN,PREECLAMPSIA,NCT03717701,Not Applicable,0.0025889774020024267,0.9974110225979976
CN(C)C(=N)NC(=N)N,_METFORMIN,RHEUMATOID ARTHRITIS,NCT04068246,Early Phase 1,0.0025889774020024267,0.9974110225979976
CN(C)C(=N)NC(=N)N,_METFORMIN,CHRONIC KIDNEY DISEASES,NCT03831464,Phase 3,0.0025889774020024267,0.9974110225979976
CN(C)C(=N)NC(=N)N,_METFORMIN,ABDOMINAL AORTIC ANEURYSM,NCT03507413,Phase 2|Phase 3,0.00977029472716953,0.9902297052728304
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,OVARIAN CANCER,NCT03378297,Early Phase 1,0.014589798084042531,0.9854102019159576
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.0101087201645257,0.9898912798354744
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,SEPSIS,NCT01784159,Phase 2,0.0005765984384891329,0.9994234015615108
CC(=O)Oc1ccccc1C(=O)O,_ASPIRIN,AORTIC STENOSIS,NCT03557242,Not Applicable,0.0005765984384891329,0.9994234015615108
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,OVARIAN CANCER,NCT03378297,Early Phase 1,0.014589798084042531,0.9854102019159576
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.0101087201645257,0.9898912798354744
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,SEPSIS,NCT01784159,Phase 2,0.0005765984384891329,0.9994234015615108
CC(=O)Oc1ccccc1C(=O)O,_ACETYLSALICYLIC_ACID,AORTIC STENOSIS,NCT03557242,Not Applicable,0.0005765984384891329,0.9994234015615108
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,_MORPHINE,CESAREAN SECTION,NCT03427463,Early Phase 1,0.021877220992148942,0.9781227790078509
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,_ICOSAPENT,ALZHEIMER DISEASE,NCT02719327,Phase 2|Phase 3,0.18311504622715635,0.8168849537728435
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,_ICOSAPENT_ETHYL,ALZHEIMER DISEASE,NCT02719327,Phase 2|Phase 3,0.20453289023126636,0.7954671097687337
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,_PENTOXIFYLLINE,SCHIZOPHRENIA,NCT04094207,Phase 1|Phase 2,0.08922503691907639,0.9107749630809238
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,PERIPHERAL ARTERIAL DISEASE,NCT03240068,Early Phase 1,0.05325413422268868,0.9467458657773112
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,RHEUMATOID ARTHRITIS,NCT03770702,Phase 3,0.014995097979697362,0.9850049020203028
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,_ANGIOTENSIN,OBESITY|HYPERTENSION,NCT03604289,Early Phase 1,0.04985761464531141,0.9501423853546884
O=C(O)CCCC[C@@H]1CCSS1,_LIPOIC_ACID,"STROKE, ISCHEMIC",NCT04041167,Phase 3,0.2313866112963838,0.7686133887036162
O=c1[nH]cc(F)c(=O)[nH]1,_FLUOROURACIL,BREAST CANCER,NCT02897700,Phase 1,0.12650717891573635,0.8734928210842634
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,_PRAVASTATIN,PREECLAMPSIA,NCT03648970,Phase 2,0.02322034231550915,0.9767796576844908
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,_DIGOXIN,ACUTE HEART FAILURE,NCT02544815,Phase 3,0.013086751278801774,0.9869132487211982
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,MULTIPLE MYELOMA,NCT04268498,Phase 2,0.11252501826604527,0.8874749817339546
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,RHEUMATOID ARTHRITIS,NCT03770923,Phase 3,0.11252501826604527,0.8874749817339546
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,ALZHEIMER DISEASE,NCT03991988,Phase 2,0.11720003248205015,0.8827999675179496
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,OVARIAN HYPERSTIMULATION SYNDROME,NCT03794037,Phase 2,0.1211593023000008,0.8788406976999993
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,_MONTELUKAST,PAIN,NCT02793375,Phase 3,0.13904361512370847,0.8609563848762914
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,_MIDAZOLAM,BREAST CANCER,NCT04172220,Not Applicable,0.013579637657922536,0.9864203623420776
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,_ROSUVASTATIN,OVARIAN CANCER,NCT03532139,Phase 2,0.17506284487568266,0.8249371551243173
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,_ROSUVASTATIN,HYPERTENSION|DYSLIPIDEMIAS,NCT04074551,Phase 3,0.004472176759410801,0.9955278232405892
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,_SIMVASTATIN,DILATED CARDIOMYOPATHY,NCT03775070,Phase 2,0.1120323098899096,0.8879676901100905
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,_EZETIMIBE,HYPERTENSION|DYSLIPIDEMIAS,NCT04074551,Phase 3,0.00887622250439046,0.9911237774956096
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,_SACUBITRIL,HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF),NCT03988634,Phase 3,0.01560641564380788,0.9843935843561921
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,ACUTE MYOCARDIAL INFARCTION,NCT02924727,Phase 3,0.007983553748472089,0.992016446251528
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,_RAMIPRIL,MYOCARDIAL INFARCTION,NCT03715998,Phase 2,0.0042909861809045215,0.9957090138190956
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,_BISOPROLOL,HEART FAILURE WITH REDUCED EJECTION FRACTION,NCT03644446,,0.1122628754938354,0.8877371245061647
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,_TELMISARTAN,PERIPHERAL ARTERY DISEASE,NCT02593110,Not Applicable,0.153265354064915,0.846734645935085
CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1,_TELMISARTAN,ALZHEIMER DISEASE,NCT02085265,Phase 2,0.004472176759410801,0.9955278232405892
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_IRBESARTAN,ESSENTIAL HYPERTENSION,NCT04488978,Phase 2,0.010999141564922479,0.9890008584350776
[C-]#[O+],_CARBON_MONOXIDE,SMOKING CESSATION,NCT03059940,Early Phase 1,0.4592385986612003,0.5407614013387996
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,_ESMOLOL,SEPTIC SHOCK,NCT03208257,Phase 2,0.07785576266455356,0.9221442373354464
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,_ESMOLOL,DIABETIC FOOT ULCER,NCT03998436,Phase 3,0.012189570611719231,0.9878104293882808
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,ALZHEIMER DISEASE,NCT04205539,Phase 1,0.18371791760420844,0.8162820823957917
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,_DEXMEDETOMIDINE,BLOOD COAGULATION DISORDER,NCT04269278,,0.14121719095164556,0.8587828090483544
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl,_ESMOLOL_HYDROCHLORIDE,DIABETIC FOOT ULCER,NCT03998436,Phase 3,0.12419659759988246,0.8758034024001177
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,HYPERTENSION|DYSLIPIDEMIAS,NCT04074551,Phase 3,0.0020692919348731546,0.9979307080651268
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,_LOSARTAN,CEREBRAL SMALL VESSEL DISEASE,NCT03082014,Phase 3,0.01710607520726385,0.9828939247927362
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,ALZHEIMER DISEASE,NCT04063124,Phase 1|Phase 2,0.6950921075029542,0.3049078924970459
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,_DASATINIB,CHRONIC KIDNEY DISEASE,NCT02848131,Phase 2,0.2951842590694977,0.7048157409305021
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,_TRAMETINIB,MULTIPLE MYELOMA,NCT03091257,Phase 1,0.4285363709834864,0.5714636290165135
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,_LENVATINIB,BREAST CANCER,NCT03168074,Phase 2,0.30038506805530585,0.6996149319446939
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,_VENETOCLAX,BREAST CANCER,NCT04298918,Phase 1|Phase 2,0.9416416439017756,0.05835835609822442
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,BREAST CANCER,NCT04170465,Phase 2,0.11012598490017457,0.889874015099825
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,HEART FAILURE,NCT03331861,Phase 2,0.17601383938912385,0.8239861606108758
CN(C)C(=N)N=C(N)N.Cl,_METFORMIN_HYDROCHLORIDE,CHRONIC KIDNEY DISEASES,NCT03831464,Phase 3,0.11077461706224956,0.8892253829377502
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,NEWLY DIAGNOSED MULTIPLE MYELOMA,NCT03742297,Phase 3,0.10247430197768358,0.8975256980223163
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,_CARFILZOMIB,MULTIPLE MYELOMA,NCT03989414,Phase 1|Phase 2,0.19850875564202736,0.8014912443579724
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,_THALIDOMIDE,THALASSEMIA,NCT03651102,Phase 2|Phase 3,0.1907233879758477,0.8092766120241522
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,PROSTATE CANCER,NCT02643667,Phase 1|Phase 2,0.3615508379283336,0.638449162071666
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,_IBRUTINIB,NON-HODGKIN'S LYMPHOMA,NCT03198026,Phase 2,0.32347082994675674,0.6765291700532429
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,_BENDAMUSTINE,MULTIPLE MYELOMA,NCT04083898,Phase 1|Phase 2,0.6805286872719214,0.3194713127280788
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,_DOXYCYCLINE,INFERTILITY,NCT03824340,Not Applicable,0.0726544832554907,0.9273455167445094
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,_DROXIDOPA,ORTHOSTATIC HYPOTENSION,NCT01370512,Phase 2,0.06972097583560624,0.9302790241643936
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,_TOPIRAMATE,SCHIZOPHRENIA,NCT02808533,Not Applicable,0.11988549750367085,0.8801145024963292
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,HEART FAILURE WITH PRESERVED EJECTION FRACTION,NCT03619213,Phase 3,0.1192731496815794,0.8807268503184207
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.005975189655209039,0.9940248103447912
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,ALZHEIMER DISEASE,NCT03801642,Phase 1|Phase 2,0.005975189655209039,0.9940248103447912
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,AGING,NCT04401904,Phase 1|Phase 2,0.005975189655209039,0.9940248103447912
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,_DAPAGLIFLOZIN,"HEART FAILURE, DIASTOLIC",NCT04475042,Phase 2,0.03463102663372973,0.9653689733662704
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,_EXENATIDE,SMOKING CESSATION,NCT02975297,Phase 1|Phase 2,0.08559820909996307,0.9144017909000368
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,_EXENATIDE,ACUTE ISCHEMIC STROKE,NCT03287076,Phase 2,0.08352540519917748,0.9164745948008226
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,_DICLOFENAC,BREAST CANCER,NCT04511832,Not Applicable,0.1483506270433054,0.8516493729566945
CC(C)Cc1ccc(C(C)C(=O)O)cc1,_IBUPROFEN,VASCULITIS,NCT03692416,Phase 3,0.009179949895777785,0.9908200501042222
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,_CIPROFLOXACIN,PNEUMONIA,NCT03177720,Phase 1,0.10117913263713008,0.8988208673628698
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,INFECTION,NCT03844776,Not Applicable,0.08272890232155378,0.9172710976784464
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,_AMOXICILLIN,PERIODONTITIS,NCT03733379,Phase 3,0.026230656284677103,0.9737693437153228
CC1=C2[N+]3=C(C=C4[N+]5=C(C(C)=C6N7[C@@H]8[C@H](CC(N)=O)[C@@]6(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)n6c[n+](c9cc(C)c(C)cc96)[Co-3]753(O)[N+]3=C1[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]83C)[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O,_HYDROXOCOBALAMIN,SEPTIC SHOCK,NCT03783091,Phase 2,0.15189590995324376,0.8481040900467559
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,GLAUCOMA,NCT04052269,Phase 3,0.03887605514142276,0.9611239448585772
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,_SILDENAFIL,BIRTH ASPHYXIA,NCT04169191,Phase 1,0.02985292433023618,0.970147075669764
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,PREECLAMPSIA,NCT03724838,Not Applicable,0.01798950525827386,0.982010494741726
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,_SILDENAFIL_CITRATE,BIRTH ASPHYXIA,NCT04169191,Phase 1,0.13703431039631325,0.8629656896036866
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,_APIXABAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.012562480238315316,0.9874375197616848
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,_APIXABAN,THROMBOSIS,NCT02981472,Phase 2,0.055317173792268366,0.9446828262077316
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,_ESOMEPRAZOLE,PREECLAMPSIA,NCT03717701,Not Applicable,0.03404216658263607,0.9659578334173641
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,_PROCALCITONIN,PNEUMONIA,NCT03711227,,0.7773656678398178,0.2226343321601821
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,_PROCALCITONIN,"KIDNEY FAILURE, CHRONIC",NCT03698877,,0.7773656678398178,0.2226343321601821
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAMPIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.3830943127365968,0.6169056872634029
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAMPICIN,INFECTIVE ENDOCARDITIS,NCT02701608,Phase 3,0.3830943127365968,0.6169056872634029
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,SCHIZOPHRENIA,NCT04369391,Phase 1,0.28071969355058746,0.7192803064494122
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,_MOXIFLOXACIN,DIABETES,NCT01984827,Phase 1,0.2678922898023934,0.7321077101976066
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,_IMIPENEM,PNEUMONIA,NCT03177720,Phase 1,0.07027634111170257,0.9297236588882976
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,_ROFLUMILAST,ASTHMA,NCT04108377,Phase 1,0.036533809519685566,0.9634661904803145
[Cl-].[Na+],_SODIUM_CHLORIDE,HEART FAILURE WITH PRESERVED EJECTION FRACTION,NCT03837470,Early Phase 1,0.43970390481414007,0.56029609518586
[Cl-].[Na+],_SODIUM_CHLORIDE,EPISTAXIS,NCT02930941,Not Applicable,0.07850986596506973,0.9214901340349301
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,INFECTION,NCT03844776,Not Applicable,0.19331781228469988,0.8066821877153002
Cc1ncc([N+](=O)[O-])n1CCO,_METRONIDAZOLE,PERIODONTITIS,NCT03733379,Phase 3,0.1184097987434849,0.8815902012565151
CN(C)C(=O)Oc1ccc[n+](C)c1,_PYRIDOSTIGMINE,ORTHOSTATIC HYPOTENSION,NCT01370512,Phase 2,0.047843689299162655,0.9521563107008376
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,_MIRABEGRON,"HYPERTROPHY, LEFT VENTRICULAR",NCT02599480,Phase 2,0.146693309571885,0.8533066904281149
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],_PYRIDOSTIGMINE_BROMIDE,ORTHOSTATIC HYPOTENSION,NCT01370512,Phase 2,0.1084300805470085,0.8915699194529914
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,LIVER CIRRHOSIS,NCT03005444,Not Applicable,0.0022034190852028997,0.9977965809147972
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.0022034190852028997,0.9977965809147972
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,NON-VALVULAR ATRIAL FIBRILLATION,NCT04174859,,0.1373739843383477,0.8626260156616522
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,_RIVAROXABAN,DEEP VEIN THROMBOSIS,NCT02722447,Phase 3,0.0022034190852028997,0.9977965809147972
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,_FLUOXETINE,TYPE 1 DIABETES,NCT03228732,Early Phase 1,0.05415685734996759,0.9458431426500324
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,_DULOXETINE,OSTEO ARTHRITIS OF THE KNEES,NCT04224584,Phase 2,0.07575985911406717,0.9242401408859326
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,HYPERTENSION,NCT02133872,Phase 1,0.3105819568728893,0.6894180431271105
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,_MINOCYCLINE,"STROKE, ISCHEMIC",NCT03320018,Phase 2|Phase 3,0.1388290045427335,0.8611709954572665
CC[C@@H](C(N)=O)N1CCCC1=O,_LEVETIRACETAM,SCHIZOPHRENIA,NCT02647437,Not Applicable,0.07567267021467991,0.92432732978532
Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1,_MILRINONE,HEART FAILURE|CARDIOMYOPATHY,NCT02077010,Phase 1,0.3988472133085144,0.6011527866914854
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,_COLCHICINE,ATRIAL FIBRILLATION|STROKE,NCT02282098,Phase 3,0.013115516202584231,0.986884483797416
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,_COLCHICINE,ESSENTIAL HYPERTENSION,NCT04303689,Not Applicable,0.02297221471402613,0.9770277852859738
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,_SPIRONOLACTONE,HEART FAILURE WITH PRESERVED EJECTION FRACTION,NCT02901184,Phase 3,0.06797000102510191,0.932029998974898
Oc1ncnc2[nH]ncc12,_ALLOPURINOL,CHRONIC KIDNEY DISEASE,NCT03990363,Phase 2,0.20868966948488868,0.7913103305151112
Oc1ncnc2[nH]ncc12,_ALLOPURINOL,HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF),NCT04327024,Phase 2,0.20868966948488868,0.7913103305151112
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,_PLERIXAFOR,MULTIPLE MYELOMA,NCT03406091,,0.6521748875293011,0.34782511247069936
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,PROSTATE CANCER,NCT02944201,Phase 2,0.0567469359761725,0.9432530640238276
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,_CARVEDILOL,BREAST CANCER,NCT03879629,Phase 2,0.08541122882640688,0.9145887711735932
CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,_ARGATROBAN,ACUTE ISCHEMIC STROKE,NCT03735979,Phase 3,0.25095158214195884,0.7490484178580408
N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O,_EPTIFIBATIDE,ACUTE ISCHEMIC STROKE,NCT03735979,Phase 3,0.2738934864840214,0.7261065135159783
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,_FENTANYL,POSTOPERATIVE DELIRIUM,NCT03120442,Not Applicable,0.003692567567567568,0.9963074324324324
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,_ONDANSETRON,BLOOD COAGULATION DISORDER,NCT04499274,Not Applicable,0.21631740621796705,0.7836825937820329
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,_ONDANSETRON,ADVERSE REACTION TO OTHER DRUGS AND MEDICINES,NCT02436798,,0.2160934431552283,0.7839065568447716
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,SUBARACHNOID HEMORRHAGE,NCT02636218,Phase 2|Phase 3,0.07940537045477535,0.9205946295452248
CNC1(c2ccccc2Cl)CCCCC1=O,_KETAMINE,CLUSTER HEADACHE,NCT04179266,Phase 1|Phase 2,0.2372763990584389,0.7627236009415611
FCOC(C(F)(F)F)C(F)(F)F,_SEVOFLURANE,ATRIAL FIBRILLATION,NCT02697448,Not Applicable,0.02536582373383415,0.974634176266166
FCOC(C(F)(F)F)C(F)(F)F,_SEVOFLURANE,HEART DISEASE,NCT03569085,Phase 1,0.2521885261680657,0.7478114738319341
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,PROLIFERATIVE DIABETIC RETINOPATHY,NCT02447185,Phase 3,0.005602710478897769,0.9943972895211022
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,_TRIAMCINOLONE,PSORIASIS,NCT04117919,Phase 2,0.01060271047889777,0.9893972895211022
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,_TRIAMCINOLONE_ACETONIDE,PROLIFERATIVE DIABETIC RETINOPATHY,NCT02447185,Phase 3,0.029067785959001006,0.9709322140409989
N=C(N)NC(=O)Cc1c(Cl)cccc1Cl,_GUANFACINE,ALZHEIMER DISEASE,NCT03116126,Phase 3,0.04360082577997245,0.9563991742200276
CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,_PIROXICAM,POSTOPERATIVE PAIN,NCT04062591,Early Phase 1,0.06460553353886128,0.9353944664611388
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,_REMIFENTANIL,ENDOSCOPIC SINUS SURGERY,NCT03417180,Not Applicable,0.004493870461936154,0.995506129538064
O=C([O-])O.[Na+],_SODIUM_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.12055071751740976,0.8794492824825899
O=C(O)O,_BICARBONATE,CHRONIC KIDNEY DISEASE,NCT02411773,Phase 2,0.24438602777811666,0.7556139722218832
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,_TIMOLOL,PRIMARY OPEN ANGLE GLAUCOMA,NCT03193333,Phase 3,0.00721015271131461,0.9927898472886854
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,_TIMOLOL,"GLAUCOMA, PRIMARY OPEN ANGLE|OCULAR HYPERTENSION",NCT04149899,Phase 1|Phase 2,0.002424578527063,0.9975754214729372
CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,_LATANOPROST,OPEN ANGLE GLAUCOMA,NCT04060758,Phase 1,0.02872859022905481,0.9712714097709452
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,_DORZOLAMIDE,PRIMARY OPEN ANGLE GLAUCOMA,NCT03193333,Phase 3,0.10053044061241856,0.8994695593875816
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,_BIMATOPROST,OPEN-ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT04285580,Phase 3,0.039479993744371,0.9605200062556288
O=S(=O)(O)CCS,_MESNA,RETINOBLASTOMA,NCT01783535,Phase 2,0.2675901461893724,0.7324098538106276
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,PREECLAMPSIA,NCT02221830,Early Phase 1,0.06191491342914698,0.9380850865708532
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,CESAREAN SECTION COMPLICATIONS,NCT03777878,Not Applicable,0.05254611531161482,0.9474538846883852
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_OXYTOCIN,POSTOPERATIVE PAIN,NCT03011307,Phase 2,0.07947700908655836,0.9205229909134416
FC(F)OC(Cl)C(F)(F)F,_ISOFLURANE,HEART DISEASE,NCT03569085,Phase 1,0.3683879179468028,0.6316120820531972
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,_ROCURONIUM,PROSTATE CANCER,NCT03808077,Phase 2,0.0809224577497486,0.9190775422502514
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,_NALBUPHINE,POSTOPERATIVE COMPLICATIONS,NCT03470077,Phase 2,0.06029358794495195,0.9397064120550479
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,_NALOXONE,PAIN,NCT04034004,Early Phase 1,0.10514597439372246,0.8948540256062776
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,_IOHEXOL,ACUTE KIDNEY INJURY,NCT02772276,Phase 2,0.16415573339961262,0.8358442666003875
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,_IOHEXOL,ACUTE RENAL FAILURE,NCT02961478,Phase 3,0.09605212732341416,0.9039478726765856
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,BURN,NCT03513406,Phase 3,0.0127063231824145,0.9872936768175856
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,_NEOSTIGMINE,POSTOPERATIVE PAIN,NCT04544228,Not Applicable,0.017796473660807482,0.9822035263391926
COc1cc(CC(C)N)c(OC)cc1C,_DOM,STROKE,NCT03828851,Not Applicable,0.4056886394420896,0.5943113605579102
COc1cc(CC(C)N)c(OC)cc1C,_DOM,HEMOPHILIA A,NCT03818763,Phase 1,0.4777087439283788,0.5222912560716213
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,"HEMATOMA, SUBDURAL, CHRONIC",NCT03582293,Phase 3,0.006323675442401356,0.9936763245575986
NC[C@H]1CC[C@H](C(=O)O)CC1,_TRANEXAMIC_ACID,EPISTAXIS,NCT02930941,Not Applicable,0.02060233319906541,0.9793976668009344
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,_MISOPROSTOL,CESAREAN SECTION COMPLICATIONS,NCT03774706,Not Applicable,0.01281168576832136,0.9871883142316784
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,_MISOPROSTOL,LABOR PAIN,NCT03829592,Not Applicable,0.01281168576832136,0.9871883142316784
[Cl-].[K+],_POTASSIUM_CHLORIDE,HEART FAILURE,NCT02840799,Phase 2,0.12638515926965993,0.8736148407303398
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],_MAGNESIUM_CITRATE,DIABETIC NEPHROPATHY,NCT03824379,Phase 2,0.12219789865802473,0.8778021013419754
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,_BROMOCRIPTINE,PERIPARTUM CARDIOMYOPATHY,NCT02590601,Phase 3,0.09136440864104016,0.90863559135896
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,_ATENOLOL,CEREBRAL SMALL VESSEL DISEASE,NCT03082014,Phase 3,0.02996253014408827,0.9700374698559118
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],_NIFEDIPINE,CHRONIC KIDNEY DISEASES,NCT03695107,,0.1959190350930813,0.8040809649069186
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,TYPE 1 DIABETES,NCT04201496,Phase 1,0.11374790170679845,0.8862520982932017
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,CHRONIC KIDNEY DISEASE,NCT03594110,Phase 3,0.09356480413172004,0.90643519586828
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,ACUTE MYOCARDIAL INFARCTION,NCT03087773,Phase 3,0.0038003657391176907,0.9961996342608824
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,_EMPAGLIFLOZIN,ACUTE DECOMPENSATED HEART FAILURE,NCT04049045,Phase 2,0.014617200420639753,0.9853827995793604
CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1,_ERTUGLIFLOZIN,TYPE 2 DIABETES,NCT04029480,Phase 3,0.2839309541602378,0.7160690458397618
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,_EVOGLIPTIN,"DIABETES MELLITUS, TYPE 2",NCT04326166,,0.35688443813686244,0.6431155618631376
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,_MARAVIROC,STROKE,NCT03172026,Phase 2|Phase 3,0.09839375791438704,0.9016062420856128
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.058875052438751116,0.9411249475612488
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_ALBUTEROL,PULMONARY HYPERTENSION,NCT03270332,Early Phase 1,0.04934447233913205,0.950655527660868
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,INSULIN RESISTANCE,NCT04558190,Not Applicable,0.058875052438751116,0.9411249475612488
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,_SALBUTAMOL,PULMONARY HYPERTENSION,NCT03270332,Early Phase 1,0.04934447233913205,0.950655527660868
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,_QUETIAPINE,POSTOPERATIVE DELIRIUM,NCT03739476,Phase 3,0.07737331505792737,0.9226266849420726
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,_LURASIDONE,BIPOLAR DISORDER,NCT02731612,Phase 3,0.22031078594340373,0.779689214056596
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.003396519577377253,0.9966034804226228
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,_CLOPIDOGREL,DIABETES MELLITUS TYPE 2,NCT04305587,Phase 1,0.0043201581027668,0.9956798418972332
Brc1c(NC2=NCCN2)ccc2nccnc12,_BRIMONIDINE,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT03450629,Phase 3,0.05039512134022853,0.9496048786597712
Brc1c(NC2=NCCN2)ccc2nccnc12,_BRIMONIDINE,PRIMARY OPEN ANGLE GLAUCOMA,NCT03193333,Phase 3,0.03954107130031145,0.9604589286996884
CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O,_TREPROSTINIL,DIABETIC FOOT ULCER,NCT03654989,Phase 1|Phase 2,0.1006324753806374,0.8993675246193625
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,_EPLERENONE,END-STAGE RENAL DISEASE,NCT02490904,Phase 3,0.003144418872266973,0.9968555811277329
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,HEART FAILURE WITH PRESERVED EJECTION FRACTION,NCT03837470,Early Phase 1,0.4318988788913679,0.5681011211086321
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,SEPTIC SHOCK,NCT04156451,Not Applicable,0.005725194691724678,0.9942748053082754
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,NASAL POLYPS,NCT03362515,Phase 2,0.002424578527063,0.9975754214729372
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,_FUROSEMIDE,NEPHROTIC SYNDROME,NCT03750136,Not Applicable,0.005725194691724678,0.9942748053082754
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,_ESTROGEN,ISCHEMIA REPERFUSION INJURY,NCT03663543,Phase 1|Phase 2,0.22497118554554285,0.7750288144544569
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,_ALPRAZOLAM,TYPE 1 DIABETES,NCT03635437,Phase 1|Phase 2,0.10327277601290777,0.8967272239870924
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,BREAST CANCER,NCT02395614,Not Applicable,0.1429319462747211,0.8570680537252789
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,INFECTION,NCT03844776,Not Applicable,0.10777814603880938,0.8922218539611907
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,_CHLORHEXIDINE,DIABETIC FOOT ULCER,NCT03503370,Phase 2,0.13313786947001524,0.8668621305299848
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,_MANNITOL,SUBARACHNOID HEMORRHAGE,NCT04135456,Not Applicable,0.09483368159719643,0.9051663184028036
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,ALZHEIMER DISEASE,NCT02792257,Phase 2,0.07126821516230086,0.9287317848376992
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,OSTEO ARTHRITIS OF THE KNEES,NCT04298528,Phase 3,0.07126821516230086,0.9287317848376992
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,_DRONABINOL,BIPOLAR DISORDER,NCT04231643,Early Phase 1,0.1670142128713085,0.8329857871286914
O=P([O-])([O-])O.[Na+].[Na+],_SODIUM_PHOSPHATE,PERIPHERAL ARTERIAL DISEASE,NCT03942601,Phase 2,0.28259265595287897,0.7174073440471207
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[Na+],_DEXAMETHASONE_SODIUM_PHOSPHATE,PERIPHERAL ARTERIAL DISEASE,NCT03942601,Phase 2,0.3901721253934498,0.6098278746065501
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,_PILOCARPINE,"GLAUCOMA, ANGLE-CLOSURE",NCT02613013,Not Applicable,0.16880284559296638,0.8311971544070336
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,_BRIMONIDINE_TARTRATE,OPEN ANGLE GLAUCOMA|OCULAR HYPERTENSION,NCT03450629,Phase 3,0.13239581403418568,0.8676041859658143
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,_EDOXABAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.019441656673392226,0.980558343326608
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,_EDOXABAN,NON-VALVULAR ATRIAL FIBRILLATION,NCT04519944,,0.21131351327738224,0.7886864867226177
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,_EDOXABAN,CARDIAC DISEASE,NCT03395639,Phase 3,0.20109029441919984,0.7989097055808
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,_EDOXABAN,AORTIC VALVE STENOSIS,NCT04171726,Phase 3,0.07449985898348169,0.9255001410165182
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,_EDOXABAN,ATRIAL FIBRILLATION AND FLUTTER,NCT03488420,,0.17515559165642097,0.8248444083435792
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1,_EDOXABAN,DEEP VEIN THROMBOSIS|VENOUS THROMBOEMBOLISM,NCT02303431,Phase 1,0.15374706697543894,0.846252933024561
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21,_DABIGATRAN,ISCHAEMIC STROKE,NCT03148457,Not Applicable,0.024131017075849127,0.9758689829241508
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,TYPE 2 DIABETES,NCT03758144,Not Applicable,0.1265849581210799,0.8734150418789199
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,_RIFAXIMIN,SYSTOLIC HEART FAILURE,NCT02637167,Phase 2,0.11306762962221682,0.886932370377783
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C,_METOLAZONE,ACUTE HEART FAILURE,NCT04163588,Phase 3,0.0435097057396109,0.9564902942603888
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,_RIMIDUCID,MULTIPLE MYELOMA,NCT03288493,Phase 1|Phase 2,0.5771743322812548,0.4228256677187452
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,_LEFLUNOMIDE,POLYMYALGIA RHEUMATICA,NCT03576794,Phase 3,0.07478285514797876,0.9252171448520212
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,_RUCAPARIB,BREAST CANCER,NCT03911453,Early Phase 1,0.4918228519910864,0.5081771480089136
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,_ZAFIRLUKAST,OVARIAN CANCER,NCT04339140,Phase 2,0.4795627241423808,0.5204372758576192
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,_SUGAMMADEX,BURN,NCT03513406,Phase 3,0.04890481170196469,0.9510951882980352
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,_FLUTICASONE,PHARMACOKINETICS,NCT03739294,Phase 2,0.08472815196218729,0.9152718480378128
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,CORONARY ARTERY DISEASE,NCT02954510,Phase 3,0.5101423721095313,0.4898576278904687
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],_FERUMOXYTOL,PULMONARY EMBOLISM,NCT03173066,Phase 1,0.5101423721095313,0.4898576278904687
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,_NICARDIPINE,ANEURYSMAL SUBARACHNOID HEMORRHAGE,NCT04269408,Phase 2,0.09201493154373196,0.907985068456268
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,_BUTORPHANOL,COLONOSCOPY,NCT04477733,Not Applicable,0.0601632490321666,0.9398367509678331
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,HYPERTENSION,NCT02425566,Phase 1,0.2631906789626894,0.7368093210373103
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,ACUTE HEART FAILURE,NCT03302910,Phase 2|Phase 3,0.12051533201177896,0.8794846679882211
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],_NITROGLYCERIN,CARDIOVASCULAR DISEASE,NCT02115724,Not Applicable,0.27285278560124704,0.7271472143987526
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,_BARICITINIB,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT03843125,Phase 3,0.3430717719090909,0.6569282280909087
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,PROSTATE CANCER,NCT03716739,Phase 2,0.11236074988471433,0.8876392501152855
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,_TESTOSTERONE,LIVER CIRRHOSIS,NCT03995251,Not Applicable,0.026930091086209237,0.9730699089137907
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,_TESTOSTERONE_ENANTHATE,PROSTATE CANCER,NCT02090114,Phase 2,0.3775580536899893,0.6224419463100106
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,_ADENOSINE,ACUTE STROKE,NCT03720522,,0.25809467733460584,0.7419053226653938
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,_ADENOSINE,CORONARY ARTERY STENOSIS,NCT04401657,Not Applicable,0.30423693504440763,0.6957630649555918
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,_ADENOSINE,PAROXYSMAL ATRIAL FIBRILLATION,NCT01672346,Phase 3,0.02327757120052479,0.9767224287994752
C=CCN.ClCC1CO1,_SEVELAMER,CHRONIC KIDNEY DISEASES,NCT04120922,Not Applicable,0.2911808461882067,0.7088191538117931
C=CC[NH3+].ClCC1CO1.O=C([O-])O,_SEVELAMER_CARBONATE,CHRONIC KIDNEY DISEASES,NCT04120922,Not Applicable,0.5017877799904988,0.4982122200095012
O=C1OC2(c3ccc(O)cc3Oc3cc(O)ccc32)c2ccccc21,_FLUORESCEIN,RETINAL VEIN OCCLUSION|MACULAR EDEMA,NCT04140448,,0.20290629062659987,0.7970937093734001
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],_GLYCOPYRROLATE,BURN,NCT03513406,Phase 3,0.14721405052532568,0.8527859494746743
CC(C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)O,_RIP,REPERFUSION INJURY,NCT03068689,Not Applicable,0.6298593816488389,0.3701406183511609
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,_TICAGRELOR,CAROTID ARTERY STENOSIS,NCT02677545,Phase 2,0.003692567567567568,0.9963074324324324
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,_BERBERINE,METABOLIC SYNDROME,NCT03976336,Not Applicable,0.08717642453557621,0.9128235754644236
O=[N+]([O-])[O-],_NITRATE,HEART FAILURE,NCT02840799,Phase 2,0.27198282402986346,0.7280171759701365
O=[N+]([O-])[O-],_NITRATE,ERECTILE DYSFUNCTION,NCT04116060,Not Applicable,0.112447283665242,0.8875527163347579
O=[N+]([O-])[O-],_NITRATE,HEART FAILURE|ARRHYTHMIA,NCT03658174,Not Applicable,0.15523382090217616,0.8447661790978236
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,_ALPROSTADIL,PERIPHERAL ARTERY DISEASE,NCT04197323,Phase 2,0.0727330855433953,0.9272669144566048
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,_MIFEPRISTONE,BREAST CANCER,NCT02788981,Phase 2,0.1926254977464447,0.8073745022535553
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,_DONEPEZIL,APHASIA|STROKE,NCT04134416,Phase 3,0.03441795607028287,0.9655820439297171
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,_DONEPEZIL,"DIABETES MELLITUS, TYPE 2",NCT04507438,Phase 2,0.0680736124808996,0.9319263875191004
NCCS.O=C(O)C(O)C(O)C(=O)O,_CYSTEAMINE_BITARTRATE,ASTHMA,NCT03883984,Phase 1,0.19193855695760914,0.8080614430423906
CC(=O)C(=O)O,_PYRUVATE,PROSTATE CANCER,NCT02913131,Phase 1|Phase 2,0.7452151747982745,0.2547848252017258
CC(=O)C(=O)O,_PYRUVATE,BREAST CANCER,NCT03121989,Phase 1,0.4131064687359588,0.5868935312640409
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,_PACRITINIB,BREAST CANCER,NCT04520269,Phase 1|Phase 2,0.3071939944282695,0.6928060055717303
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,_TERBUTALINE,IMMUNE THROMBOCYTOPENIA,NCT04481282,Phase 2,0.2782842860701133,0.7217157139298862
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,_DANAZOL,IMMUNE THROMBOCYTOPENIA,NCT04481282,Phase 2,0.5498774300694815,0.4501225699305185
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,_GRANISETRON,SEPSIS,NCT03924518,Phase 2,0.040512154972293074,0.9594878450277068
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,_LEVOSIMENDAN,ST ELEVATION MYOCARDIAL INFARCTION,NCT03699215,Phase 3,0.0009115929941618014,0.9990884070058382
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,_LEVOSIMENDAN,ACUTE DECOMPENSATED HEART FAILURE,NCT04158674,Phase 3,0.0009115929941618014,0.9990884070058382
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,_LEVOSIMENDAN,"CARDIAC OUTPUT, LOW",NCT04179604,Phase 2|Phase 3,0.01573839944612645,0.9842616005538736
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,_CARBETOCIN,CESAREAN SECTION COMPLICATIONS,NCT03777878,Not Applicable,0.053122213054855004,0.946877786945145
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,_ILOPROST,SEPTIC SHOCK,NCT04123444,Phase 2|Phase 3,0.015047870778875852,0.9849521292211242
COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC,_TERAZOSIN,CAROTID ARTERY STENOSIS,NCT03195673,Phase 2,0.1050390422812002,0.8949609577187997
CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,_PROPAFENONE,PERSISTENT ATRIAL FIBRILLATION,NCT02633774,Not Applicable,0.02764288371524446,0.9723571162847554
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,_PIMAVANSERIN,SCHIZOPHRENIA,NCT04531982,Phase 3,0.2694429602118575,0.7305570397881427
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,_TOMIVOSERTIB,BREAST CANCER,NCT04261218,Phase 1,0.4853505479689049,0.5146494520310951
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,_SEMAGLUTIDE,TYPE 1 DIABETES,NCT03899402,Phase 2|Phase 3,0.10375068654889548,0.8962493134511046
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,_SUCROSE,PAIN,NCT04313179,Not Applicable,0.08575843509162351,0.9142415649083764
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,PAIN,NCT04132609,Not Applicable,0.3758055472476656,0.6241944527523342
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,OBSTRUCTIVE SLEEP APNEA,NCT02666781,,0.4671788596463273,0.5328211403536727
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,_BIA,ANXIETY,NCT04245501,Not Applicable,0.4370662853260144,0.5629337146739856
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,_HESPERIDIN,METABOLIC SYNDROME,NCT03734874,Not Applicable,0.041635402862059114,0.9583645971379408
O=[O+][O-],_OZONE,ISCHEMIC HEART DISEASE,NCT03660657,Phase 2|Phase 3,0.1906847572614239,0.8093152427385758
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,_FLUTICASONE_FUROATE,PHARMACOKINETICS,NCT03739294,Phase 2,0.15858441585300515,0.8414155841469948
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,_CANAGLIFLOZIN,HEART FAILURE,NCT04252287,Phase 3,0.15277605175867612,0.8472239482413241
CC(O)C(=O)[O-].[Na+],_SODIUM_LACTATE,SEPTIC SHOCK,NCT03528213,Phase 2|Phase 3,0.13829350103181878,0.8617064989681809
CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,_FIMASARTAN,ESSENTIAL HYPERTENSION,NCT03991442,Phase 3,0.06187495456148759,0.9381250454385124
[133Xe],_XENON-133,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,NCT03331302,Phase 1|Phase 2,0.5288381025333566,0.4711618974666433
CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1,_SELEXIPAG,"HYPERTENSION, PULMONARY",NCT04175600,Phase 3,0.3482988634719472,0.6517011365280528
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,_OMECAMTIV_MECARBIL,HEART FAILURE WITH REDUCED EJECTION FRACTION,NCT03759392,Phase 3,0.5395846846747514,0.4604153153252487
Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1,_ANAGLIPTIN,TYPE 2 DIABETES,NCT04267601,,0.37695921048281256,0.6230407895171872
O=N[O-],_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.8026814726704333,0.1973185273295667
O=N[O-],_NITRITE,OUT-OF-HOSPITAL CARDIAC ARREST,NCT03452917,Phase 2|Phase 3,0.8026814726704333,0.1973185273295667
O=N[O-].[Na+],_SODIUM_NITRITE,HEART FAILURE,NCT02713126,Phase 2,0.8767829625820472,0.12321703741795252
O=N[O-].[Na+],_SODIUM_NITRITE,OUT-OF-HOSPITAL CARDIAC ARREST,NCT03452917,Phase 2|Phase 3,0.8767829625820472,0.12321703741795252
CCCCC1OC(=O)c2ccccc21,_BUTYLPHTHALIDE,CEREBRAL SMALL VESSEL DISEASE,NCT04078204,Not Applicable,0.02346568103944672,0.9765343189605534
CCCCC1OC(=O)c2ccccc21,_BUTYLPHTHALIDE,VASCULAR DEMENTIA,NCT03804229,Phase 3,0.1527027523820068,0.8472972476179932
Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1,_NETARSUDIL,"GLAUCOMA, OPEN-ANGLE",NCT04234932,Early Phase 1,0.2559060776414984,0.7440939223585015
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,_ITI-214,"HEART FAILURE, SYSTOLIC",NCT03387215,Phase 1|Phase 2,0.5129670183354149,0.487032981664585
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1,_APROCITENTAN,RESISTANT HYPERTENSION,NCT03541174,Phase 3,0.7404161936076938,0.25958380639230616
O=C[C@H](O)[C@H](O)[C@H](O)CO,_RIBOSE,PROSTATE CANCER,NCT03334500,Early Phase 1,0.3462858409618525,0.6537141590381474
O=[Se]([O-])[O-].[Na+].[Na+],_SODIUM_SELENITE,HEART DISEASE,NCT02002247,Phase 3,0.3927906615248501,0.6072093384751499
CCCCCCCC(=O)OC[C@H](NC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)O,_GHRELIN,PERIPHERAL ARTERY DISEASE,NCT04377126,Phase 2,0.3755411664601985,0.6244588335398013
C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@@]21C,_DEOXYCHOLIC_ACID,ADIPOSITY,NCT04054011,Early Phase 1,0.38425922631579706,0.6157407736842029
CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1,_CARIPRAZINE,SCHIZOPHRENIA,NCT03817502,Phase 3,0.4784005560620781,0.5215994439379217
CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1,_LASMIDITAN,MIGRAINE DISORDERS,NCT04396574,Phase 3,0.44387539104069496,0.5561246089593049
Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1,_ALPELISIB,BREAST CANCER,NCT03056755,Phase 2,0.4755396829135697,0.5244603170864303
COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1,_ERDAFITINIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.3871607497875176,0.6128392502124822
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,_DAROLUTAMIDE,PROSTATE CANCER,NCT04136353,Phase 3,0.25530940390493034,0.7446905960950696
CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1,_ENASIDENIB,RELAPSED REFRACTORY MULTIPLE MYELOMA,NCT03732703,Phase 1|Phase 2,0.3391007368658674,0.6608992631341323
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1,_ZANUBRUTINIB,WALDENSTRÃ–M MACROGLOBULINEMIA,NCT04463953,Phase 2,0.24888968334745376,0.7511103166525462
CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12,_UPADACITINIB,SYSTEMIC LUPUS ERYTHEMATOSUS,NCT04451772,Phase 2,0.4268270248962341,0.5731729751037659
C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F,_UBROGEPANT,MIGRAINE DISORDERS,NCT04492020,Phase 3,0.3493917913848488,0.650608208615151
